We are financed by world class investors

We are ambitious – The OMass pipeline is weighted towards programs addressing homogeneous, specialty care patient populations aligned with our intent to build integrated development and commercialization capabilities. Our pipeline also includes targets addressing large indications where OMass expects to partner in order to realize the full value of our programs.

Supportive and experienced investors – Originally a spinout from Oxford University, OMass is backed by a top-tier investor syndicate.

Syncona's purpose is to invest to extend and enhance human life. Syncona does this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Oxford Science Enterprises (OSE) is a science business builder. OSE Builds world-changing businesses, bringing Oxford science to the world faster.

OMass has benefited from an Innovate UK grant to support the development of its platform. Innovate UK is the United Kingdom's innovation agency, which provides money and support to organisations to make new products and services.

Stay up-to-date Our Latest News
OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical...
OMass Announces Publication in Nature Methods
Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in...
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
Oxford, 25 February 2020 - OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton - OMass Therapeutics...